Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 15/20 | 0.32 |
| ▸ | RICTOR | Q6R327 | 13/20 | 0.32 |
| ▸ | MAPKAP1 | Q9BPZ7 | 13/20 | 0.32 |
| ▸ | MLST8 | Q9BVC4 | 13/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688690 | 1.00 | MEN1 (0.35) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL1688480 | 0.88 | MEN1 (0.35) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL1688476 | 0.88 | MEN1 (0.35) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL5934778 | 0.87 | MTOR (0.32) | MEN1LMNAKMT2ATRPM8MTOR | |
| SCHEMBL5934764 | 0.87 | MTOR (0.32) | MEN1LMNAKMT2ATRPM8MTOR | |
| SCHEMBL2688281 | 0.85 | GAA (0.34) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL1688532 | 0.85 | GAA (0.34) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL2690033 | 0.84 | TRPM8 (0.35) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL2688782 | 0.84 | TRPM8 (0.35) | MEN1LMNAKMT2AGAATRPM8 | |
| SCHEMBL2689919 | 0.84 | MEN1 (0.35) | MEN1LMNAKMT2AGAATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661268-A2 | INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012048129-A2 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | MEN1 3607/4885LMNA 1693/4885KMT2A 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.